Prognostic and predictive values of transcriptomic signatures in metastatic pancreatic cancer: A biomarker analysis of three French multicenter prospective randomized controlled phase 2 trials (Prodige35, Prodige37 and AFUGEM).

Cancer LettJul 28, 2026 (epub)
Clinical ResearchOncology (Medical)

Shulin Zhao, Remy Nicolle, Julien Taieb et al.

✦ AI-curated · Sources linked

In 30 seconds

This study analyzed transcriptomic signatures in 178 patients with metastatic pancreatic cancer from three phase 2 trials. The immune classical subtype demonstrated superior median progression-free survival (PFS) of 9.03 months and overall survival (OS) of 11.27 months compared to other subtypes. The findings suggest that transcriptomic signatures can inform prognosis and treatment strategies.

Key findings

  • Immune classical subtype showed a median PFS of 9.03 months and OS of 11.27 months.
  • Higher classical component correlated with improved OS (HR=0.737, p=0.005).
  • Inactive stroma predicted better PFS (HR=0.66, p=0.003) and OS (HR=0.697, p=0.013).
  • GemPred-negative patients treated with FOLFIRINOX had longer PFS (8.2 vs. 2.3 months; HR=2.28, p=0.008).

Why it matters

Understanding the prognostic and predictive values of transcriptomic signatures can enhance treatment decision-making in metastatic pancreatic cancer, potentially leading to improved patient outcomes.

Source

PubMed · PMID 42521075

Published in Cancer Lett. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.